Middle East Respiratory Syndrome (MERS) Vaccines
As of May 11, 2021, the U.S. CDC had not approved a MERS-CoV prevention vaccine.
MERS-COV Vaccine Candidates
VTP-500 (ChAdOx1) MERS-CoV is a vaccine candidate from the University of Oxford that consists of the replication-deficient simian adenovirus vector ChAdOx1, containing the MERS Spike protein antigen. The VTP-500 vaccine is administered alone both as a single administration and with a homologous prime-booster.
INO-4700 MERS-CoV is a DNA plasmid vaccine that expresses the MERS CoV spike (S) glycoprotein.
MVA MERS (Modified Vaccinia virus Ankara) is a vaccine candidate that contains the full-length spike gene of MERS-CoV.
NOTE: This page's content is sourced from the U.S. CDC, FDA, WHO, clinicaltrials.gov, and the Precision Vax network of websites. This information was last fact-checked by healthcare providers, such as Dr. Robert Carlson.